What is the 13F Pro Quality Score for YARW?

13F Pro ranks Yarrow Bioscience, Inc. (YARW) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View YARW's current score at https://13fpro.ai/company/YARW (free sign-up required for the full ranking).

Where does 13F Pro source YARW data?

All Yarrow Bioscience, Inc. fundamentals and ownership data come directly from SEC EDGAR. Yarrow Bioscience, Inc. files with the SEC under CIK 1566044. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is YARW in?

Yarrow Bioscience, Inc. (YARW) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is YARW research updated on 13F Pro?

YARW's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Yarrow Bioscience, Inc.(YARW)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1566044 YARW stock profile & AI dashboard →

13F Pro Quality Score

15.2/100

Rank #2,855 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why YARW Scores 15/100

exact factor attribution · 2026-09-11

YARW's composite is driven by institutional flow and earnings growth, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+2.5 pts

100th pct

Earnings growth

+2.2 pts

95th pct

Shareholder dilution

-2.4 pts

3th pct

Capital efficiency

-4.0 pts

10th pct

Earnings quality

-4.5 pts

5th pct

Profitability

-7.1 pts

3th pct

Revenue growth

-7.1 pts

14th pct

Free cash flow

-7.2 pts

2th pct

Scale

-7.3 pts

2th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

YARW Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Yarrow Bioscience, Inc. (YARW), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores YARW at 15.2/100 on a 32-signal composite quality model, placing it at rank #2,855 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Yarrow Bioscience, Inc. reports quarterly revenue of $97.0K, net income of $-3.0M. Top institutional holders of YARW by reported 13-F value include ADAR1 Capital Management, Nantahala Capital Management, Lynx1 Capital Management, based on the most recent SEC filings. YARW trades on the Nasdaq exchange and files with the SEC under CIK 1566044. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate YARW daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Yarrow Bioscience, Inc. directly from SEC EDGAR. Yarrow Bioscience, Inc.'s 13F Pro composite quality score has ranged between 12 and 15 since 2026, currently 15.2 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q2 2026

$97.0K

Net Income

Q2 2026

$-3.0M

ROIC

Q2 2026

-56.2%

D/E Ratio

Q2 2026

0.00

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+13.8% YoY

$570.0KFY 2025

FY22 $477.0KFY23 $424.0KFY24 $501.0KFY25 $570.0K

Net Income

+33.5% YoY

$-26.5MFY 2025

FY22 $-23.2MFY23 $-28.5MFY24 $-39.8MFY25 $-26.5M

Operating Income

+31.8% YoY

$-29.7MFY 2025

FY22 $-34.3MFY23 $-29.3MFY24 $-43.6MFY25 $-29.7M

EPS (Diluted)

+33.3% YoY

$-0.62FY 2025

FY22 $-7.28FY23 $-2.78FY24 $-0.93FY25 $-0.62

Total Assets

-54.9% YoY

$30.2MFY 2025

FY22 $40.8MFY23 $97.7MFY24 $66.9MFY25 $30.2M

Total Debt

$0.00FY 2025

FY22 $0.00FY23 $0.00FY24 $0.00FY25 $0.00

Op. Cash Flow

+2.5% YoY

$-33.1MFY 2025

FY22 $-29.2MFY23 $-25.3MFY24 $-34.0MFY25 $-33.1M

Free Cash Flow

+2.8% YoY

$-33.1MFY 2025

FY22 —FY23 $-25.3MFY24 $-34.1MFY25 $-33.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$570.0K +13.8%	$501.0K +18.2%	$424.0K -11.1%	$477.0K -48.8%	$931.0K -95.6%	$21.0M
Net Income	$-26.5M +33.5%	$-39.8M -40.0%	$-28.5M -22.6%	$-23.2M +68.3%	$-73.3M +71.3%	$-255.6M
Operating Income	$-29.7M +31.8%	$-43.6M -49.1%	$-29.3M +14.7%	$-34.3M +11.9%	$-38.9M +84.6%	$-252.5M
EPS (Diluted)	$-0.62 +33.3%	$-0.93 +66.5%	$-2.78 +61.8%	$-7.28 +71.6%	$-25.64 -425.4%	$7.88
Total Assets	$30.2M -54.9%	$66.9M -31.5%	$97.7M +139.7%	$40.8M -39.2%	$67.0M -28.5%	$93.7M
Total Debt	$0.00	$0.00	$0.00	$0.00	$0.00 -100.0%	$33.2M
Operating Cash Flow	$-33.1M +2.5%	$-34.0M -34.1%	$-25.3M +13.2%	$-29.2M +48.2%	$-56.4M +58.9%	$-137.1M
Free Cash Flow	$-33.1M +2.8%	$-34.1M -34.5%	$-25.3M	—	$-56.4M +58.9%	$-137.2M

Get alerted when YARW's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Yarrow Bioscience, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of YARW

ADAR1 Capital Management, LLC
$1.9M2,950,000 sh
Nantahala Capital Management, LLC
$1.3M2,000,000 sh
Lynx1 Capital Management LP
$1.1M1,628,700 sh
Shay Capital LLC
$947.8K1,456,651 sh
T3 Companies, LLC
$614.9K945,000 sh
BRAIDWELL LP
$596.1K916,077 sh
KVP Capital Advisors, LP
$325.7K500,551 sh
CITADEL ADVISORS LLC
$304.8K468,457 sh
TWO SIGMA INVESTMENTS, LP
$285.5K438,818 sh
ACADIAN ASSET MANAGEMENT LLC
$248.0K381,797 sh

Fund	Value	Shares
ADAR1 Capital Management, LLC	$1.9M	2,950,000
Nantahala Capital Management, LLC	$1.3M	2,000,000
Lynx1 Capital Management LP	$1.1M	1,628,700
Shay Capital LLC	$947.8K	1,456,651
T3 Companies, LLC	$614.9K	945,000
BRAIDWELL LP	$596.1K	916,077
KVP Capital Advisors, LP	$325.7K	500,551
CITADEL ADVISORS LLC	$304.8K	468,457
TWO SIGMA INVESTMENTS, LP	$285.5K	438,818
ACADIAN ASSET MANAGEMENT LLC	$248.0K	381,797

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put YARW on your watchlist

Track score changes the day Yarrow Bioscience, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is YARW a good stock to buy?

13F Pro's AI-powered analysis of Yarrow Bioscience, Inc. (YARW) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for YARW are available on the YARW stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. YARW is classified as a small company.

Which hedge funds own YARW?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling YARW. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Yarrow Bioscience, Inc.'s investment landscape.